Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI plus cetuximab as first-line treatment in metastatic colorectal cancer (pilot phase II)
2006-004991-10Phase 2Completed
- Sponsor
- University Hospital of Heraklion, Department of Medical Oncology
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colon cancer (mCRC), sponsored by University Hospital of Heraklion, Department of Medical Oncology. Primary endpoint: Objective Response Rate. Started Feb 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2006-004991-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004991-10.